QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.094128v1 316/3/1262    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engström, M. Articles by Wurster, S. Search for Related Content PubMed PubMed Citation Articles by Engström, M. Articles by Wurster, S.

CELLULAR AND MOLECULAR

Differential Efficacies of Somatostatin Receptor Agonists for G-Protein Activation and Desensitization of Somatostatin Receptor Subtype 4-Mediated Responses

Juvantia Pharma Ltd., Turku, Finland

Although desensitization represents an important physiological feedback mechanism that protects against overstimulation, it can significantly limit the therapeutic usefulness of drugs. In the current investigation, we have employed Cytosensor microphysiometry for the purpose of determining the propensity of somatostatin receptor agonists to induce desensitization of the human somatostatin receptor subtype 4 (h sst₄)-mediated extracellular acidification rate (EAR) response in intact Chinese hamster ovary (CHO) cells. We have compared this propensity with the efficacies of the agonists as measured in a [³⁵S]guanosine-5'-O-(3-thio)triphosphate binding assay with membranes of the same CHO-h sst₄ cell line. We observed that (1'S,2S)-4-amino-N-(1'-carbamoyl-2'-phenylethyl)-2-(4''-methyl-1''-naphthalenesulfonylamino)butanamide (J-2156), a superagonist at the h sst₄ with higher efficacy than somatostatin-14 itself (Engström et al., 2005), was considerably less prone to cause desensitization of the EAR response than somatostatin-14, somatostatin-28, and cortistatin-17. In contrast, compound A (methyl (2S)-5-{[amino(imino)methyl]amino}-2-{[4-[5–7-difluoro-2-phenyl-1H-indol-3-yl)butanoyl]amino}-pentanoate), which we also found to be an h sst₄ superagonist, albeit to a lesser degree than J-2156, demonstrated a high propensity to cause desensitization. Our results indicate that there is no relationship between the efficacy of the agonists to cause G-protein activation and their ability to induce desensitization of the h sst₄-mediated EAR responses. The finding that on the h sst₄, J-2156 is not only a superagonist but also shows a low propensity to cause desensitization, might offer therapeutic advantages. At a minimum, the compound will be a powerful tool to study the mechanisms connected to efficacy and desensitization of h sst₄-mediated responses.

Address correspondence to: Mia Engström, Juvantia Pharma Ltd., Lemminkäisenkatu 5, FIN-20520 Turku, Finland. E-mail: mia.engstrom{at}juvantia.com

This article has been cited by other articles:

				C. Qiu, T. Zeyda, B. Johnson, U. Hochgeschwender, L. de Lecea, and M. K. Tallent Somatostatin Receptor Subtype 4 Couples to the M-Current to Regulate Seizures J. Neurosci., April 2, 2008; 28(14): 3567 - 3576. [Abstract] [Full Text] [PDF]